3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl; hydrochloride | 61655-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl; hydrochloride
• 英文别名: 1-(2-pyrazinyl)piperazine hydrochloride；2-piperazin-1-ylpyrazine;hydrochloride
• CAS: 61655-78-5
• 化学式: C₈H₁₂N₄*ClH
• mdl: MFCD08692031
• 分子量: 200.671
• InChiKey: OTDNHTMVWNAZKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-{[(5-Chloro-2-methoxyphenyl)sulfonyl]amino}benzoic acid 、 3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl; hydrochloride 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以31.6%的产率得到5-chloro-2-methoxy-N-(4-(4-(pyrazin-2-yl)piperazine-1-carbonyl)phenyl)benzene-sulfonamide
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS AND COMPOSITIONS

  摘要：

  本文描述了调节丙酮酸激酶M2（PKM2）的化合物和含有这些化合物的组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。

  公开号：

  US20100331307A1
• 作为产物：
  描述：

  tert-butyl 4-(pyrazin-2-yl)piperazine-1-carboxylate 在 盐酸 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl; hydrochloride
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS AND COMPOSITIONS

  摘要：

  本文描述了调节丙酮酸激酶M2（PKM2）的化合物和含有这些化合物的组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。

  公开号：

  US20100331307A1

文献信息

• 2,4-Diamino-6,7-dimethoxyquinazolines. 3. 2-(4-heterocyclylpiperazin-1-yl) derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents
  作者：Simon F. Campbell、Rhona M. Plews

  DOI：10.1021/jm00393a019

  日期：1987.10

  alpha-adrenoceptor affinity and antihypertensive activity. These quinazoline derivatives showed high binding affinity (ca. 10(-10) M) and selectivity (greater than 10,000) for alpha 1-adrenoceptors in vitro, with no relevant activity at alpha 2 sites. Several compounds displayed similar activity to prazosin (Ki = 1.9 X 10(-10) M) while the dimethoxytriazine derivative 30 (Ki = 8 X 10(-11) M) was more potent. Like

  制备了一系列的4-氨基-6,7-二甲氧基-2（4-杂环基哌嗪-1-基）喹唑啉（3），并筛选了α-肾上腺素受体亲和力和降压活性。这些喹唑啉衍生物在体外对α1-肾上腺素受体具有高结合亲和力（约10（-10）M）和选择性（大于10,000），在α2位点无相关活性。几种化合物显示出与哌唑嗪（Ki = 1.9 X 10（-10）M）相似的活性，而二甲氧基三嗪衍生物30（Ki = 8 X 10（-11）M）更有效。像prazosin（pA2 = 8.37 +/- 0.24）一样，30被证明是有效的（pA2 = 8.63 +/- 0.15），去甲肾上腺素的α1介导的血管收缩作用的竞争性拮抗剂。系列3的高结合亲和力最可能是由于在生理pH下形成了质子化的α1-肾上腺素受体药效基团33，加上喹唑啉2取代基的有效疏水相互作用。哌唑嗪和30的计算机辅助叠加表明，糠酰和二甲氧基三嗪部​​分之间几乎没有结构对应，而且
• [EN] HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS<br/>[FR] DERIVES DE CARBONYLE SUBSTITUES HETEROCYCLIQUES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR DE LA DOPAMINE D3
  申请人：AVENTIS PHARMA INC

  公开号：WO2002066446A1

  公开（公告）日：2002-08-29

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson s Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington s Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D¿3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地结合多巴胺D3受体。另一方面，本发明涉及一种用于治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的过程，以及将所述化合物用作多巴胺D3受体成像剂的方法。
• 5-HT receptor ligands and uses thereof
  申请人：Chiang Phoebe

  公开号：US20050090503A1

  公开（公告）日：2005-04-28

  Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT 2 receptors in animals are described herein.

  本文描述了化学式（IA）的化合物，其作为5-HT受体配体，并且在治疗与动物体内5-HT2受体激活相关的疾病方面的用途。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor
  申请人：Aventis Pharmaceutical Inc.

  公开号：US20040220173A1

  公开（公告）日：2004-11-04

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，该衍生物显示出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者给予所述化合物的治疗有效量以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程以及将其作为多巴胺D3受体成像剂的方法。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。